OncoSignal
Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:20 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

NCT07408089 · Boundless Bio, Inc. · PHASE1 · terminated · last registry update 2026-08-19 · Breast cancer · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

KindQuoteOur categorySource
Stated“The study was terminated primarily due to a business decision related to a corporate transaction and was not driven by any safety signal.”–Registry record, Boundless Bio, Inc.

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against ESR1 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

  • Internal portfolio and board discussions
  • Unpublished trial data and interim analyses
  • Terms of any partner or licence decision